The 58 startups in Hub71+ Life Sciences, the health and life sciences arm of Abu Dhabi tech ecosystem Hub71, have raised US$463 million (AED 1.7 billion) between them and generated US$138 million (AED 506.8 million) in revenue in the programme’s first year.
Hub71 set up the specialist ecosystem with Abu Dhabi’s Department of Health, the Emirates Drug Establishment and the Health, Endurance, Longevity and Medicine (HELM) cluster. It now has 15 strategic partners, the latest being Johnson & Johnson and Mediclinic Middle East.
Johnson & Johnson will work with startups tackling hard problems in surgery, offering mentoring, technology infrastructure and possible routes to commercial deals. Mediclinic Middle East will look at new technologies in its priority areas, among them cancer care, women’s health and the management of chronic disease.
Basma AlBadi AlDhaheri, head of growth and value creation at Hub71, said: “In its first year, Hub71+ Life Sciences has made important progress in connecting startups with healthcare institutions, enabling opportunities for clinical validation, research and commercial collaboration.”
Deals across the portfolio
BioSapien, which develops cancer treatment technology, has secured regulatory and ethics approvals to move its MediChip platform towards Phase I clinical trials in Abu Dhabi. MediChip is a 3D-printed implant that breaks down in the body and is designed to release chemotherapy at the site of the tumour. BioSapien also raised US$7.5 million in a round led by Global Ventures.
Nabdh signed a memorandum of understanding with M42 to scale its AI health technology, a deal that included the launch of its Smart Health Mirror for early health assessments. BioTwin is working with Abu Dhabi Biobank on precision health research that combines AI with genomic data.
Ovasave, a fertility and hormonal health platform registered with the Department of Health, is offering fertility and menopause benefits to companies through insurers and brokers. It has supported more than 10,000 women and couples and has raised US$1.2 million so far.
Unilabs Middle East has teamed up with two of the startups: Takalam, a digital mental well-being platform, and GlycanAge, which measures biological age.
Nikolina Lauc, co-founder and chief executive of GlycanAge, said: “Our partnership with Unilabs Middle East is an important step towards making biological-age testing more widely available through its healthcare network and expanding our presence in the Middle East.”
The HELM cluster is projected to add AED 94 billion to Abu Dhabi’s GDP by 2045.
The photo above was issued by Hub71 with the announcement.